Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Liabilities (2016 - 2025)

RedHill Biopharma has reported Total Liabilities over the past 15 years, most recently at $21.1 million for Q4 2025.

  • Quarterly Total Liabilities fell 7.26% to $21.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.1 million through Dec 2025, down 7.26% year-over-year, with the annual reading at $21.1 million for FY2025, 7.26% down from the prior year.
  • Total Liabilities was $21.1 million for Q4 2025 at RedHill Biopharma, down from $22.8 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $203.2 million in Q3 2022 and troughed at $741000.0 in Q4 2023.
  • The 5-year median for Total Liabilities is $56.8 million (2023), against an average of $94.9 million.
  • Year-over-year, Total Liabilities crashed 98.48% in 2022 and then skyrocketed 2966.94% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $172.3 million in 2021, then crashed by 98.48% to $2.6 million in 2022, then tumbled by 71.75% to $741000.0 in 2023, then skyrocketed by 2966.94% to $22.7 million in 2024, then decreased by 7.26% to $21.1 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Total Liabilities are $21.1 million (Q4 2025), $22.8 million (Q2 2025), and $22.7 million (Q4 2024).